Refeyn establishes new mass photometry Scientific Advisory Board to maximize potential of transformative technology

Mass photometry’s unique bioanalytical workflow capabilities recognized by the scientific community, with over 500 scientific publications in just six years

Oxford, UK (16 September, 2024) – Refeyn, the company behind pioneering mass photometry technologies, announces that it has established a new Scientific Advisory Board, chaired by Justin Benesch, Professor of Biophysical Chemistry, Oxford University and co-founder of Refeyn. To recognize and help realize the full potential of mass photometry’s unique bioanalytical workflow capabilities, the new board includes external scientific experts in pharmaceutical and biologics discovery, process development and manufacture.

The transformative capabilities and applications of mass photometry are evident in the rapid adoption of this novel light-based bioanalytical technology. Launched just six years ago, mass photometry has now been cited in more than 500 scientific papers, and is used in hundreds of labs around the world. The new Scientific Advisory Board will convene regularly to explore and evaluate the transformative potential of mass photometry in critical customer workflows. This panel of experts will provide strategic guidance on the most impactful applications of this cutting-edge technology, ensuring that Refeyn solutions continue to meet and exceed the evolving needs of customers.

Alongside Refeyn’s academic founders from Oxford University, Professors Justin Benesch and Philipp Kukura, the external members to the Scientific Advisory Board bring a significant breadth of understanding in key mass photometry applications:

·         Louise Duffy, Ph.D., Chief Technology Officer and Chief Quality Officer, Abzena, a CDMO focusing on antibody-drug conjugates and complex-to-manufacture biologics

·         Daniel Galbraith, Ph.D., Chief Scientific Officer, Solvias, a CRO/CDMO with a focus on cell & gene therapy products and biologics

·         Volker Germaschewski, Ph. D., Senior Director Therapeutic Platforms, LifeArc, with a background in antibody-based formats of biologics, various vaccine technologies and nucleic acid-based therapeutics

·         Del Trezise, Ph.D., a life science tools and applications consultant, and Technology Scout at Sartorius AG

“The potential for mass photometry in life science is enormous. As it measures mass at the single molecule level in a matter of minutes while maintaining a native environment, it can provide unique insights into the composition and function of even complex samples and molecular mechanisms,” said Professor Benesch, Oxford University. “The Scientific Advisory Board is helping to define some of the questions we can answer using this revolutionary technique, and to understand those that are of particular importance in meeting biotech industry needs.”

“The Scientific Advisory Board is supporting us by focusing in on the key applications where the integration of mass photometry as a highly efficient bioanalytical tool can make a fundamental difference in life science workflows,” added Gerry Mackay, Refeyn’s CEO. “There is potential not only in biologics research and discovery, but also within the bioprocessing space. The board is also assisting us in evaluating longer-term prospects for innovation and the further development of mass photometry and other ground-breaking technologies.”

Also supporting Refeyn in its aim to put molecular mass measurement capabilities within easy reach for scientists is a wider community of domain experts and Key Opinion Leaders. This broader pool of scientific advisors provides valuable input in many areas where Refeyn’s unique products are making a difference, including: Biomolecular analytics such as antibody characterization, protein-protein interactions and membrane protein analytics, as well as vector analytics.

To find out more about Refeyn and its novel mass photometry technologies, please visit: https://www.refeyn.com